My Cancer Genome News: Pfizer Independent Grant for Learning & Change Award

The My Cancer Genome team, in collaboration with the Knowledge Management team in the Vanderbilt Eskind Biomedical Library, has been awarded a Pfizer Independent Grant for Learning & Change entitled: "Learning style assessment in healthcare professionals to address knowledge gaps around novel treatment strategies to overcome resistance to endocrine therapy in ER+ breast cancer."

This one-year award, with Dr. Mia Levy as the Principal Investigator (PI) and Dr. Sheila Kusnoor as the co-PI, will fund developing and evaluating educational materials tailored to different learning styles in order to educate clinicians about novel treatment strategies to overcome resistance to endocrine therapy in ER+ breast cancer. In conjunction with the educational materials, a set of breast cancer content pages will be published on My Cancer Genome. The new content pages will include new page types covering drug classes in specific diseases.

Immunotherapy in Cancer on My Cancer Genome

My Cancer Genome has launched the new content section Immunotherapy in Cancer accessible from the Molecular Medicine menu on the home page. In this section, information on three classes of drugs is covered: CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors.

As part of this new content section, page types outside of the standard disease, gene, and variant structure on My Cancer Genome have been
created. The new page types include information on (1) classes of drugs and (2) specific drugs in a particular disease. This content expands My Cancer Genome's drug-based content beyond the List of Anticancer Agents page. The immunotherapy content currently focuses on melanoma, non-small cell lung cancer, and small cell lung cancer. Immunotherapy content will be updated and expanded to include additional drugs, drug classes, and diseases.

### Myelodysplastic Syndromes Content on My Cancer Genome

Content covering Myelodysplastic syndromes (MDS) and 14 related genes and variant groups has been published on My Cancer Genome. MDS are a group of myeloid neoplasms originating in hematopoietic stem cells, characterized by ineffective hematopoiesis and an increased risk of progression to acute myeloid leukemia (AML).

Genes along several cellular pathways can be involved in MDS, including RNA splicing, DNA methylation, chromatin modification, transcription, DNA repair control, cohesin function, the RAS pathway, and DNA replication. Mutations in several genes have been shown to have prognostic significance; these include ASXL1, BCOR, ETV6, EZH2, RUNX1, TET2, and TP53. Others have been associated with decreased or improved outcomes, although the associations have not been shown to be statistically significant: DNMT3A, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2.

The section editors for this new disease section are Stephen A. Strickland, M.D., MSCI and Annette S. Kim, M.D., Ph.D. Dr. Strickland is an Assistant Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt. Dr. Kim is an Assistant Professor of Pathology, Microbiology and Immunology in the Division of Hematology/Oncology at Vanderbilt.

### Update on the National Leadership Grant from the Institute of Museum and Library Services (IMLS)

The Vanderbilt Knowledge Management team, working in collaboration with the My Cancer Genome team, has created a Knowledge Pearls Database to educate patients about genetics.
This free, publically available website includes short videos, called “Knowledge Pearls,” which were developed in-house to explain the meaning of terms regarding genetics or cancer medicine found on the My Cancer Genome website that patients may have difficulty understanding. Development of the videos was guided by a review of suitability guidelines and criteria and by comments from focus group discussions with cancer patients and caregivers. Although the terms were selected based on a review of My Cancer Genome content, the videos were created to be broadly applicable to multiple health conditions. This project was partially funded by a National Leadership Grant (IMLS LG-06-13-0180-13).

Contact: mycancergenome@vanderbilt.edu - Copyright © 2015 MY CANCER GENOME